ClinicalTrials.gg
CompletedNCT05437055Updated Nov 3, 2026Results posted

THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing

An interventional study of Mechanical Thrombectomy (Penumbra System with Thunderbolt) in Acute Ischemic Stroke and Large Vessel Occlusion, sponsored by Penumbra Inc.. Completed at 32 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Penumbra Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Ischemic Stroke by Penumbra Inc. — 2 open to participants now, 2 under way, none of them phase 3. Ischemic Stroke · Penumbra Inc..

Started
2022
the only one that year
No phase
3 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Ischemic Stroke by Penumbra Inc., this one is the only one that started in 2022, is one of 3 with no phase, and was the 12th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

2 of the 14 studies in Ischemic Stroke by Penumbra Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Ischemic Stroke by Penumbra Inc., or all of them as a file.
02

Study summary

The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.

03

Conditions studied

  • Acute Ischemic Stroke
  • Large Vessel Occlusion

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • AIS
  • Large Vessel Occlusion
  • LVO
  • Mechanical Thrombectomy
  • Penumbra System
  • Thunderbolt Aspiration Tubing
  • A Direct Aspiration First Pass Technique
  • ADAPT
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age 18 - 80 years
  2. Treatment within 8 hours of symptom onset
  3. Pre-stroke mRS 0-2
  4. Patient experiencing acute ischemic stroke secondary to intracranial large vessel occlusion in the internal carotid, middle cerebral (M1 or M2), basilar, or vertebral artery
  5. If patient is eligible for thrombolytic therapy, it was administered as soon as possible, and no later than 3 hours from stroke symptom onset
  6. Planned frontline treatment with Penumbra System including Thunderbolt modulated aspiration
  7. obtained per Institution Review Board/Ethics Committee requirements

Exclusion criteria

Exclusion Criteria:

  1. Stenosis, excessive tortuosity, or any occlusion in a proximal vessel requiring treatment or preventing access to the thrombus
  2. Alberta Stroke Program Early CT Score (ASPECTS) ≤6 or core infarct volume >50 mL on MRI or CT-based imaging (for anterior circulation strokes)
  3. Pregnant patient
  4. \< 90 days due to comorbidities
  5. Current participation in an interventional drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were but have since become commercially available are not considered investigational studies
  6. Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Single Arm

    Use of Penumbra System including Thunderbolt in patients with acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy

    Device: Mechanical Thrombectomy (Penumbra System with Thunderbolt)

Interventions

  • DeviceMechanical Thrombectomy (Penumbra System with Thunderbolt)

    Subject will receive Penumbra System with Thunderbolt

06

What researchers measure

Primary outcomes

  1. Efficacy Endpoint: Angiographic Revascularization

    Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2b or higher. \*mTICI ranges from 0-3, with higher grading representing better outcome

    Time frame: Up to Procedure Completion

Secondary outcomes

  1. Efficacy Endpoint: Angiographic Revascularization After First Pass

    Angiographic revascularization of the occluded target vessel after first pass as defined by mTICI 2b or higher \*mTICI ranges from 0-3, with higher grading representing better outcome

    Time frame: During Index Procedure

  2. Efficacy Endpoint: Angiographic Revascularization

    Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2c or higher \*mTICI ranges from 0-3, with higher grading representing better outcome

    Time frame: Up to Procedure Completion

  3. Efficacy Endpoint: Time to Revascularization

    Time from arterial puncture to successful revascularization of the target vessel (mTICI 2b-3), or to the final angiogram if successful revascularization is not achieved

    Time frame: During Index Procedure

  4. Efficacy Endpoint: Modified Rankin Scale (mRS)

    Functional outcomes measured by mRS 0-2 at 90 days (0 no symptoms - 5 severe disability)

    Time frame: 90 Days Post-Procedure

  5. Safety Endpoint: Rate of Symptomatic Intracranial Hemorrhage (sICH)

    Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours

    Time frame: 24 hours Post-Procedure

  6. Safety Endpoint: All-cause Mortality

    All-cause mortality at 90 days post-procedure

    Time frame: 90 Days Post-Procedure

  7. Safety Endpoint: Serious Adverse Events (SAEs)

    Incidence of device related, and/or procedure related Serious Adverse Events (SAEs) within 24 hours post-procedure

    Time frame: Up to 24 hours Post-Procedure

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneSingle Arm
Started216
Completed182
Not completed34

Outcome measures

PrimaryEfficacy Endpoint: Angiographic Revascularization

Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2b or higher. \*mTICI ranges from 0-3, with higher grading representing better outcome

Time frame:
Up to Procedure Completion
Reported as:
Count of participants · Participants
Efficacy Endpoint: Angiographic Revascularization
ParticipantsSingle Arm
Efficacy Endpoint: Angiographic Revascularization189
SecondaryEfficacy Endpoint: Angiographic Revascularization After First Pass

Angiographic revascularization of the occluded target vessel after first pass as defined by mTICI 2b or higher \*mTICI ranges from 0-3, with higher grading representing better outcome

Time frame:
During Index Procedure
Reported as:
Count of participants · Participants
Efficacy Endpoint: Angiographic Revascularization After First Pass
ParticipantsSingle Arm
Efficacy Endpoint: Angiographic Revascularization After First Pass140
SecondaryEfficacy Endpoint: Angiographic Revascularization

Angiographic revascularization of the occluded target vessel Post-Penumbra as defined by mTICI 2c or higher \*mTICI ranges from 0-3, with higher grading representing better outcome

Time frame:
Up to Procedure Completion
Reported as:
Count of participants · Participants
Efficacy Endpoint: Angiographic Revascularization
ParticipantsSingle Arm
Efficacy Endpoint: Angiographic Revascularization152
SecondaryEfficacy Endpoint: Time to Revascularization

Time from arterial puncture to successful revascularization of the target vessel (mTICI 2b-3), or to the final angiogram if successful revascularization is not achieved

Time frame:
During Index Procedure
Reported as:
Mean · minutes
Efficacy Endpoint: Time to Revascularization
minutesSingle Arm
Efficacy Endpoint: Time to Revascularization27 ± 26
SecondaryEfficacy Endpoint: Modified Rankin Scale (mRS)

Functional outcomes measured by mRS 0-2 at 90 days (0 no symptoms - 5 severe disability)

Time frame:
90 Days Post-Procedure
Reported as:
Count of participants · Participants
Efficacy Endpoint: Modified Rankin Scale (mRS)
ParticipantsSingle Arm
Efficacy Endpoint: Modified Rankin Scale (mRS)112
SecondarySafety Endpoint: Rate of Symptomatic Intracranial Hemorrhage (sICH)

Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours

Time frame:
24 hours Post-Procedure
Reported as:
Count of participants · Participants
Safety Endpoint: Rate of Symptomatic Intracranial Hemorrhage (sICH)
ParticipantsSingle Arm
Safety Endpoint: Rate of Symptomatic Intracranial Hemorrhage (sICH)2
SecondarySafety Endpoint: All-cause Mortality

All-cause mortality at 90 days post-procedure

Time frame:
90 Days Post-Procedure
Reported as:
Count of participants · Participants
Safety Endpoint: All-cause Mortality
ParticipantsSingle Arm
Safety Endpoint: All-cause Mortality24
SecondarySafety Endpoint: Serious Adverse Events (SAEs)

Incidence of device related, and/or procedure related Serious Adverse Events (SAEs) within 24 hours post-procedure

Time frame:
Up to 24 hours Post-Procedure
Reported as:
Count of participants · Participants
Safety Endpoint: Serious Adverse Events (SAEs)
ParticipantsSingle Arm
Safety Endpoint: Serious Adverse Events (SAEs)6

Adverse events

Collected over Procedure, 24-Hour Follow-Up (+/- 12 hours), 7-10 Day and/or Discharge, 30 Day Follow-Up (+/- 7 Days), 90 Day Follow-Up (+/- 14 Days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm24/205 (11.7%)89/216 (41.2%)126/216 (58.3%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventSingle Arm
Stroke in evolutionNervous system disorders9/216
Atrial fibrillationCardiac disorders8/216
Acute respiratory failureRespiratory, thoracic and mediastinal disorders8/216
Acute kidney injuryRenal and urinary disorders5/216
Pneumonia aspirationInfections and infestations4/216
Brain oedemaNervous system disorders4/216
Cerebral artery occlusionNervous system disorders4/216
AnaemiaBlood and lymphatic system disorders3/216
Acute myocardial infarctionCardiac disorders3/216
DysphagiaGastrointestinal disorders3/216
Most frequent other events
Showing 10 of 165
Most frequent other events
EventSingle Arm
HeadacheNervous system disorders14/216
Cerebral haemorrhageNervous system disorders13/216
Deep vein thrombosisVascular disorders12/216
Atrial fibrillationCardiac disorders11/216
Haemorrhagic transformation strokeNervous system disorders10/216
Urinary tract infectionInfections and infestations9/216
Acute kidney injuryRenal and urinary disorders9/216
Urinary retentionRenal and urinary disorders9/216
ConstipationGastrointestinal disorders8/216
HypotensionVascular disorders8/216

Baseline characteristics

Age, Continuous
Age, Continuous(years)Single Arm
Mean64.8 ± 11.55
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female98
Male118
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm
American Indian or Alaska Native1
Asian3
Native Hawaiian or Other Pacific Islander1
Black or African American40
White160
More than one race5
Unknown or Not Reported6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm
Hispanic or Latino23
Not Hispanic or Latino169
Unknown or Not Reported24
Body Mass Index
Body Mass Index(kg/m2)Single Arm
Mean29.8 ± 6.96
08

Study locations

32 sites
  • Abrazo West Campus
    Goodyear, Arizona 85395, United States
  • Sharp Grossmont
    San Diego, California 92123, United States
  • HRI - Swedish
    Englewood, Colorado 80113, United States
  • Yale New Haven
    New Haven, Connecticut 06520, United States
  • Christiana Care
    Newark, Delaware 19718, United States
  • Jackson Memorial (U. of Miami)
    Miami, Florida 33136, United States
  • St. Joseph - BayCare
    Tampa, Florida 33614, United States
  • Piedmont Hospital Atlanta
    Atlanta, Georgia 30309, United States
  • Wellstar Kennestone Hospital
    Marietta, Georgia 30060, United States
  • North Shore U.
    Evanston, Illinois 60201, United States
  • Edward Elmhurst Health
    Naperville, Illinois 60540, United States
  • Indiana U. Health
    Indianapolis, Indiana 46202, United States
  • KUMC
    Kansas City, Kansas 66160, United States
  • Massachusetts General
    Boston, Massachusetts 02114, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • Abbott Northwestern
    Minneapolis, Minnesota 55427, United States
  • St. Dominic
    Jackson, Mississippi 39216, United States
  • Nebraska Medical
    Omaha, Nebraska 68198, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • University of Buffalo
    Buffalo, New York 14203, United States
  • Stonybrook U.
    Stony Brook, New York 11794, United States
  • New Hanover Regional
    Wilmington, North Carolina 28401, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Wellspan York
    York, Pennsylvania 17403, United States
  • MUSC
    Charleston, South Carolina 29425, United States
  • Fort Sanders
    Knoxville, Tennessee 37916, United States
  • Methodist U.
    Memphis, Tennessee 38104, United States
  • UT Houston
    Houston, Texas 77030, United States
  • Christus Trinity Medical Center
    Tyler, Texas 75702, United States
  • Riverside Regional Medical Center
    Newport News, Virginia 23601, United States
  • Valley Medical Center
    Renton, Washington 98055, United States
09

References and documents

Publications

  • Fiorella D, Woodward K, Matouk C, Levy EI, Kaminsky I, Reuland KS, Nickele C, Ammirati G, Starke RM, Ares WJ, Nahhas M, Mahapatra A, Sultan-Qurraie A, Bohnstedt B, Paul AR, Frei D. Thunderbolt System for acute ischemic stroke secondary to large vessel occlusion: primary results of the THUNDER study. J Neurointerv Surg. 2026 Aug 6:jnis-2026-025894. doi: 10.1136/jnis-2026-025894. Online ahead of print. PubMed 42562636 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2024, 25 months.

Results were first posted in Nov 2026, 2 years 1 month after primary completion.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 25 months is close to that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2022
First posted
Jun 29, 2022
StartActual
Aug 11, 2022
Primary completionActual
Sep 23, 2024
CompletionActual
Dec 10, 2024
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameEfficacy Endpoint: Angiographic RevascularizationImmediate Post Procedure → Up to Procedure Completion
  • DescriptionEfficacy Endpoint: Angiographic Revascularization: how it is measured was reworded
Nov 3, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42562636 ↗
Nov 3, 2026
Secondary outcomes
1 edited, 3 time frame changed, 2 description edited
What changed in the outcomes
  • EditedSafety Endpoint: All-cause mortalityMortalityTime frame: 90 Days Post-Procedure
  • Time frameEfficacy Endpoint: Angiographic Revascularization After First PassIndex Procedure → During Index Procedure
  • Time frameEfficacy Endpoint: Angiographic RevascularizationImmediate Post Procedure → Up to Procedure Completion
  • Time frameEfficacy Endpoint: Time to RevascularizationIndex Procedure → During Index Procedure
  • DescriptionEfficacy Endpoint: Angiographic Revascularization: how it is measured was reworded
  • DescriptionEfficacy Endpoint: Time to Revascularization: how it is measured was reworded
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42562636 ↗
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameEfficacy Endpoint: Angiographic RevascularizationImmediate Post Procedure → Up to Procedure Completion
    • DescriptionEfficacy Endpoint: Angiographic Revascularization: how it is measured was reworded
    Secondary outcomes 1 edited, 3 time frame changed, 2 description edited
    What changed in the outcomes
    • EditedSafety Endpoint: All-cause mortalityMortalityTime frame: 90 Days Post-Procedure
    • Time frameEfficacy Endpoint: Angiographic Revascularization After First PassIndex Procedure → During Index Procedure
    • Time frameEfficacy Endpoint: Angiographic RevascularizationImmediate Post Procedure → Up to Procedure Completion
    • Time frameEfficacy Endpoint: Time to RevascularizationIndex Procedure → During Index Procedure
    • DescriptionEfficacy Endpoint: Angiographic Revascularization: how it is measured was reworded
    • DescriptionEfficacy Endpoint: Time to Revascularization: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05437055
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Aug 11, 2022
Primary completion
Sep 23, 2024
Completion
Dec 10, 2024
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Donald Frei, M.D.
principal investigator · HCA HealthONE, LLC (Swedish Medical Center)
David Fiorella, M.D.
principal investigator · The Research Foundation for The State University of New York (Stony Brook University)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion